Abstract submission for ISMND 2022 is closed. We thank the submitters and authors for their contributions to the scientific program.

Dear ISMND 2022 participants,

The International Society for Molecular Neurodegeneration (ISMND) is welcoming you to our exciting meeting ISMND 2022 in historical Athens, Greece, or from a location of your choice.

We are thrilled that you join us to discuss recent groundbreaking science to further our understanding of the molecular mechanism underlying neurodegenerative diseases to inform advanced diagnosis and innovative therapy. ISMND 2022, this year in a timely hybrid format, offers great opportunities for scientists in the field of molecular neurodegeneration to attend invited talks by leading experts in the field, short-talks selected from submitted abstracts, as well as vibrant poster presentations either onsite or virtually.

Accumulating evidence including recent cutting-edge discoveries propose both disease-specific and disease-overlapping roles of glial cells in the pathophysiology of neurodegenerative diseases. Furthermore, regulation and function of the cerebrovasculature, blood-flow, and the integrity of the blood-brain-barrier are frequently affected in neurodegenerative conditions. With the conference theme Glial and Vascular Contributions to Neurodegenerative Diseases, the ISMND 2022 program addresses scientific progress in elucidating important non-neuronal pathological mechanisms implicated in the development and progression of various neurodegenerative diseases including Alzheimer’s disease and related disorders.

ISMND 2022 in collaboration with Molecular Neurodegeneration and with the support of the BrightFocus Foundation, provides ample opportunities to learn, network, create, and nourish scientific collaborations. We wish you a productive and stimulating conference.

 

Yours sincerely,

The ISMND 2022 Organizing Committee

 

        

Important Dates

Congress Dates: October, 10 - 12, 2022

Abstract Submission Opening: May 3rd, 2022

Abstract Submission Deadline extended until: July 15th, 2022

Follow us on